Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Breast

Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

51 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Phase 2 Recruiting

520 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

Phase 2 Active not recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

Phase 2 Not yet recruiting

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Phase 2 Active not recruiting

62 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03289819 2021-04-08

NIB

Phase 2 Completed

53 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04676997 2020-12-21

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Phase 2 Unknown

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04437160 2020-06-18

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Phase 2 Recruiting

286 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02789332 2020-03-17

GeparOla

Phase 2 Completed

107 enrolled

Breast

Kenny-Caffey syndrome, Type 1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01276769 2011-11-16

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Phase 2 Unknown

80 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

MK-5890-003

TARMAC

neoMono

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

NeoTENNIS

KEYPARTNER

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

HIFU

NIB

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

GeparOla

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer